LifeSci Capital analyst Charles Zhu maintained a Buy rating on Zymeworks today and set a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu’s rating is based on the promising outlook for Zymeworks’ ongoing clinical trials and potential financial gains. The Phase 3 HERIZON-GEA-01 trial, which is expected to deliver topline data in the second half of 2025, shows potential for strong progression-free survival (PFS) results in the treatment arms involving Zymeworks’ drug, zanidatamab, combined with chemotherapy. This anticipated success could lead to significant sales and royalty revenues, with estimates exceeding $1.7 billion in worldwide sales and over $250 million in peak annual royalties.
Furthermore, Zymeworks stands to benefit from its partnerships with JAZZ Pharmaceuticals and ONC, which could provide substantial back-end economic advantages. The analysis suggests that the trial’s design and expected outcomes are favorable, with a potential for higher PFS in certain patient groups. Despite some investor concerns about enrollment and data timelines, the overall outlook remains positive, supporting the Buy rating for Zymeworks’ stock.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZYME in relation to earlier this year.